Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (August 4th Preview)
-
Regulatory shift on gray-market peptides and compounding access
An FDA advisory committee approved moving six of seven “gray market” peptide compounds off the FDA’s CAT2 designation and onto the 503A bulk substance list, according to the committee’s vote and the evidence presented during a two-day meeting. The action would allow state-licensed physicians and pharmacists to compound and prescribe the peptide products. The committee decision ran counter to FDA expert recommendations to disallow all seven compounds based on current scientific evidence, including concerns about characterization gaps, limited safety information, immunogenicity and contamination risks, and insufficient clinical data. The peptides have been marketed alongside DIY injectables amid expanding interest fueled by GLP-1-related demand. Backlash focused on potential conflicts of interest, with six of 14 panelists reporting ties to private peptide clinics; those associated with peptide therapies voted to pass or abstained across the compounds considered. The FDA has not approved any products; the vote affects only the intermediate step of moving substances into a compounding category.
-
R&D measurement and outcome assessment gaps driving neurologic trial failures
A new study argues that many neurologic and psychiatric clinical trial failures stem less from biology and more from measurement tools that cannot detect meaningful treatment effects. The authors contend that commonly used clinical outcome assessment (COA) instruments lack sensitivity for the specific dimensions that interventions are meant to improve. The paper highlights that developing new treatments requires innovation in outcome decision-making—either tailoring existing instruments or building new COAs to close “validity gaps.” The authors point to broader COA guidance efforts, including frameworks discussed by the European College of Neuropsychopharmacology in 2024. By tying failure rates to measurement limitations, the study sets up a practical mandate for trial designers: match endpoints and instruments to the biology and expected clinical change, rather than relying on legacy scales that may miss signal.
-
Precision oncology enters earlier prostate-cancer setting with Pluvicto label expansion
The FDA expanded Novartis’ radioligand therapy Pluvicto into an earlier stage of PSMA-positive prostate cancer by granting supplemental approval for patients with metastatic hormone-sensitive prostate cancer receiving an androgen receptor pathway inhibitor plus androgen deprivation therapy. The decision nearly doubles the eligible population relative to prior approvals limited to metastatic castration-resistant disease lines. Novartis’ application was supported by data from the PSMAddition program, where the Pluvicto regimen cut the risk of disease progression or death versus standard of care alone. The company also reported safety results aligned with Pluvicto’s established profile. With Pluvicto now spanning across metastatic prostate cancer stages where PSMA is present, the label expansion intensifies competition in nuclear medicine earlier in the treatment journey and increases demand for PSMA testing infrastructure.
-
Radiopharma consolidation: Curium to acquire Lantheus in up-to-$8B deal
Curium and Lantheus announced a definitive agreement under which Curium will buy all outstanding Lantheus shares for $102.50 each in cash at closing, with potential contingent value rights that could lift the total value to about $8 billion. The transaction is expected to close in the first half of 2027, subject to Lantheus shareholder approval and regulatory clearances. The tie-up would combine Curium’s global manufacturing and theranostics footprint with Lantheus’ U.S. radiodiagnostics franchise, including prostate cancer imaging agent Pylarify and cardiac ultrasound agent Definity. Lantheus has indicated it will suspend 2026 guidance due to the pending deal and will release second-quarter results without an investor call. Analysts framed the logic around end-to-end coverage across nuclear medicine supply chain capabilities and broader commercial reach for theranostics and diagnostics products.
-
CNS portfolio merger: Supernus to combine with Indivior in all-stock deal
Supernus Pharmaceuticals and Indivior agreed to a “merger of equals” to create a CNS-focused company under the Supernus name. The transaction is structured as an all-stock deal with an expected close in the fourth quarter of 2026 and a one-time special cash dividend to Indivior shareholders prior to close. The combined company will bring a commercial portfolio spanning addiction, ADHD, depression, and Parkinson’s disease, including Indivior’s Sublocade, which recorded nearly $1 billion in sales over the 12 months ending June 30, 2026. The companies also cited structural synergies and forecast about $125 million in cost savings. The merger positions Supernus to scale execution across multiple CNS indications and adds a broader set of commercial assets while maintaining a concentrated therapeutic focus.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.